TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22814329
Drug: Oral posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral posaconazole 200 mg three times per day
Study: 17983400
Drug: 16‐week regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16‐week regimen (weekly therapy with cytoxan, adriamycin, vincristine, methotrexate, and 5‐FU)
Study: 15727949
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) alone
Study: 15727949
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) plus Testosterone (T)
Study: 15727949
Drug: Testosterone (T)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (T) plus Growth Hormone (GH)
Study: 15727949
Drug: Combined treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatments (GH and T)
Study: 12402373
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml saline instillation
Study: 12402373
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml saline instillation
Study: 12402373
Drug: 0 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 ml saline instillation (no saline)
Study: 8074058
Drug: Diluted meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted meal (2671 kJ/L, 950 mL)
Study: 8074058
Drug: Concentrated meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated meal (7452 kJ/L, 350 mL)
Study: 7114587
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (500 mg)
Study: 25641731
Drug: Simultaneous dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous dosage of ascorbic acid and aspirin
Study: 23732903
Drug: Pentavalent rotavirus
Normalized name: Vaccine product containing only live pentavalent Rotavirus antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent rotavirus vaccine RV5 (RotaTeq™), 3-dose regimen
Study: 12928710
Drug: Prostaglandin E(1)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E(1) injection before CTAP
Study: 12928710
Drug: No prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prostaglandin E(1) injection (group A)
Study: 11211541
Drug: Monthly structured
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly structured interventions for six months (Group 1, n = 42)
Study: 22901308
Drug: SAMe 1600
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMe 1600 mg
Study: 22901308
Drug: SAMe 800
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMe 800 mg
Study: 15887009
Drug: Valdecoxib 20
Normalized name: valdecoxib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 20 mg single dose on day 1 and 20 mg twice daily on days 4-7, followed by a single morning dose on day 8.
Study: 9799756
Drug: Cyclic or
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic or continuous hormone replacement therapy (HRT) with an estrogen analog (tibolone)
Study: 2199209
Drug: Inhaled frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled frusemide (approximately 28 mg)
Study: 23689947
Drug: GHRH (tesamorelin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (tesamorelin, 1 mg/d)
Study: 18483726
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/day after an induction period of 3 mg/day for 2 weeks)
Study: 11951094
Drug: Cilostazol 50
Normalized name: cilostazol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 50 mg twice daily
Study: 7885426
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (800 micrograms)
Study: 2198211
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg sultamicillin (STM) b.i.d.
Study: 2198211
Drug: 625 mg
Normalized name: betaine 625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 625 mg amoxicillin/clavulanate (AMX/CLA) t.i.d.
Study: 333869
Drug: Calcium clofibrate
Normalized name: Clofibrate
DrugBank: Clofibrate (DB00636)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium clofibrate (2 g)
Study: 21041163
Drug: Cholestyramine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (12 g)
Study: 333869
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcium clofibrate and calcium carbonate (2 + 2 g)
Study: 28012035
Drug: Sorafenib (4-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (4-week treatment prior to surgery)
Study: 28012035
Drug: Placebo (4-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4-week treatment prior to surgery)
Study: 25359924
Drug: Interferon-alpha (IFN-α)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN-α) antiviral therapy
Study: 19786646
Drug: Sesame supplementation
Normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sesame supplementation (25 g/d of sesame, approximately 50 mg/d of sesame lignan)
Study: 15182126
Drug: Propranolol (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.05 mg/kg)
Study: 11429668
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) in combination with clarithromycin for 14 days
Study: 11429668
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) used alone or in combination with other antibiotics
Study: 11429668
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with a proton pump inhibitor, clarithromycin and either amoxicillin or a nitroimidazole (tinidazole or metronidazole)
Study: 11429668
Drug: Analogous regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analogous regimens with RBC in place of proton pump inhibitors
Study: 9099655
Drug: Combination diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination diet rich in fruits, vegetables, and low-fat dairy products
Study: 9099655
Drug: Combination diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination diet (hypertensive subjects)
Study: 9099655
Drug: Combination diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination diet (non-hypertensive subjects)
Study: 2854762
Drug: Naloxone (NAL)
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone (NAL) infusion (5 mg bolus + 2.1 mg/h for 7 h)
Study: 2854762
Drug: Tamoxifen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (10 mg twice daily for 6 weeks)
Study: 2854762
Drug: Naloxone (NAL)
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone (NAL) infusion after tamoxifen administration
Study: 30111294
Drug: Ondansetron 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.05 mg/kg (group O1)
Study: 30111294
Drug: Ondansetron 0.1
Normalized name: ONDANSETRON 0.16MG/ML D5W INJ BAG 50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.1 mg/kg (group O2)
Study: 27625082
Drug: Olmesartan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (20 mg per day)
Study: 25547319
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education program (DVD)
Study: 9576425
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 to 40 mg once daily
Study: 7872726
Drug: High-dose gestagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose gestagen treatment (500 mg MPA i.m. twice weekly for three months)
Study: 3124432
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low dosage of cytosine arabinoside (3mg/m2/twice daily)
Study: 3124432
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low dosage of cytosine arabinoside (3mg/m2/twice daily) with androgens
Study: 30282393
Drug: Intraarticular methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular methylprednisolone injection
Study: 26692193
Drug: ACT‐453859 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT‐453859 (400 mg once daily or 100 mg twice daily)
Study: 26692193
Drug: Setipiprant (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setipiprant (not specified dosage)
Study: 22421745
Drug: Raltegravir (RAL)
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir (RAL) 400 mg + Atazanavir (ATV) 300 mg twice daily for 4 weeks followed by RAL 800 mg + ATV/ritonavir 300/100 mg once daily for 4 weeks
Study: 16274368
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (ergocalciferol, initially 10,000 IU weekly then 1,000 IU daily)
Study: 11354390
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg IR clarithromycin tablets twice daily for 7 days (AECB) or 14 days (AMS)
Study: 11354390
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg (2 x 500 mg) ER clarithromycin tablets once daily for 7 days (AECB) or 14 days (AMS)
Study: 3308731
Drug: Buflomedil, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil, 600 mg daily for 4 weeks
Study: 28284473
Drug: Positive Expiratory
Normalized name: AerobiKA Oscillating Positive Expiratory Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive Expiratory Pressure (PEP) therapy
Study: 25218610
Drug: Oxycodone/Naloxone prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/Naloxone prolonged-release (OXN PR)
Study: 25218610
Drug: Oxycodone prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone prolonged-release (OxyPR)
Study: 16955243
Drug: Levocetirizine (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine (1.25 mg, 2.5 mg, 5 mg)
Study: 16955243
Drug: Desloratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine (10 mg)
Study: 8514070
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of lidocaine spray
Study: 29431520
Drug: trans-resveratrol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: trans-resveratrol (300 mg)
Study: 27611858
Drug: DAPA (SGLT2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPA (SGLT2 inhibitor)
Study: 27611858
Drug: DAPA (SGLT2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPA (SGLT2 inhibitor) + PPAR-γ inhibitor GW9662
Study: 25281710
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2 i.v. on day 1 of a 21-day cycle)
Study: 12472787
Drug: Progression from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progression from macroalbuminuria to elevated plasma creatinine or renal replacement therapy (RRT)
Study: 10224345
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g) given intravenously at the induction of anesthesia
Study: 10224345
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g) given intravenously at the induction of anesthesia
Study: 6349538
Drug: Lentinan (LNT)
Normalized name: lentinan
DrugBank: Lentinan (DB13480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentinan (LNT) administered intravenously at doses of 1 mg/person/day twice a week or 2 mg/person/day once a week in combination with mitomycin C + 5-FU (MF) or tegafur (FT)
Study: 6349538
Drug: Control therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy: MF or FT alone
Study: 6349538
Drug: Lentinan (LNT)
Normalized name: lentinan
DrugBank: Lentinan (DB13480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentinan (LNT) as supportive therapy for advanced or recurrent breast cancer
Study: 31794512
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's wort (300 mg thrice daily)
Study: 28682677
Drug: Polyhexanide/betaine gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyhexanide/betaine gel
Study: 25079928
Drug: Continuous ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuous ranibizumab (0.5 mg monthly)
Study: 25079928
Drug: Discontinuous ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Discontinuous ranibizumab (0.5 mg as-needed)
Study: 25079928
Drug: Continuous bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuous bevacizumab (1.25 mg monthly)
Study: 25079928
Drug: Discontinuous bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Discontinuous bevacizumab (1.25 mg as-needed)
Study: 19531929
Drug: Intermittent ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent ART (drug conservation group; DC)
Study: 15465622
Drug: Double-immunofluorescence using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-immunofluorescence using Abeta antibodies
Study: 11204435
Drug: Osteoprotegerin (OPG)
Normalized name: Osteoprotegerin recombinant
DrugBank: AMGN-0007 (DB06511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteoprotegerin (OPG) 3.0 mg/kg
Study: 9435420
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor-I (IGF-I) at 5 micrograms/kg/h in a continuous s.c. infusion
Study: 9435420
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) at 0.03 IU/kg/daily s.c. injection
Study: 7905730
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interferon gamma (0.1 mg subcutaneously for 10 days)
Study: 31676145
Drug: ≥60 mL/kg/24
Approvals — FDA: no, EMA: no, PMDA: no
Description: ≥60 mL/kg/24 h
Study: 31676145
Drug: <60 mL/kg/24
Approvals — FDA: no, EMA: no, PMDA: no
Description: <60 mL/kg/24 h
Study: 22286628
Drug: Intermittent sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent sequential compression (ISC) of legs
Study: 10964334
Drug: Doxil 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxil 35 mg/m2 every 3 weeks
Study: 10789595
Drug: Doxil 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxil 45 mg/m2 every 3 weeks
Study: 10964334
Drug: Doxil 50
Normalized name: Doxil 50 MG in 25 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxil 50 mg/m2 every 4 weeks
Study: 10789595
Drug: Doxil 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxil 60 mg/m2 every 4 weeks
Study: 10964334
Drug: Doxil 65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxil 65 mg/m2 every 5 weeks
Study: 10964334
Drug: Doxil 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxil 70 mg/m2 every 6 weeks
Study: 10964334
Drug: Doxil (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxil (various doses)
Study: 1463155
Drug: Enoximone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 1.25 mg/kg
Study: 19108662
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) at varying doses (placebo, 0.15 mg/kg t.i.d., 0.3 mg/kg t.i.d., and 0.6 mg/kg t.i.d.) combined with behavior modification therapy (BMOD) at three intensities (no, low, high) for 3 weeks each.
Study: 19108662
Drug: Behavior modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior modification therapy (BMOD) at three intensities (no, low, high) for 3 weeks each.
Study: 14622664
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine sulfate delivery system
Study: 10831478
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (75, 150, or 225 mg/day)
Study: 9335387
Drug: 1.0 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mmol/L dialysate calcium
Study: 9335387
Drug: 1.25 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mmol/L dialysate calcium
Study: 8382725
Drug: RRVxDS-1 (serotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRVxDS-1 (serotype 2 vaccine)
Study: 8382725
Drug: RRVxD (serotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRVxD (serotype 1 vaccine)
Study: 31813658
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate sodium (PPS) monotherapy for 16 weeks
Study: 30646043
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning model predicting 30-day mortality from chemotherapy start
Study: 30646043
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning model predicting 30-day mortality among patients receiving palliative chemotherapy
Study: 8937963
Drug: Previous use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous use of azole therapy
Study: 8937963
Drug: More than
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More than five episodes of oral candidosis in the last year
Study: 2868748
Drug: Fenoldopam 25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam 25, 50, or 100 mg (dose-ranging study)
Study: 2868748
Drug: Fenoldopam 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam 100 mg (double-blind study)
Study: 2868748
Drug: Fenoldopam 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam 100 mg (after 1 month of 4 times daily dosing)
Study: 24858821
Drug: Cloxacillin 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloxacillin 4 g i.v. (intervention group)
Study: 18439587
Drug: Sequential media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential media system
Study: 11258691
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) DPI, 100 microg, twice daily
Study: 11258691
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) DPI, 200 microg, twice daily
Study: 11258691
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) MDI, 168 microg, twice daily
Study: 9610859
Drug: Disinfection solution
Normalized name: ALCOHOL 375 mL in 500 mL EXTRACORPOREAL GEL [yeQuick-dry Hand Disinfection Solution]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disinfection solution
Study: 22118014
Drug: Immediate non-occlusal
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate non-occlusal implant loading
Study: 22118014
Drug: Early non-occlusal
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early non-occlusal implant loading
Study: 30877622
Drug: DFN-02 (sumatriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFN-02 (sumatriptan 10 mg nasal spray)
Study: 12229137
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine 1.5 mg.kg‐1
Study: 12229137
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.75 ml.kg‐1
Study: 9881390
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (L and C)
Study: 10212082
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (250 microg/puff, two puffs, 12 hourly for 14 days)
Study: 27687307
Drug: ACF (Adriamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACF (Adriamycin 35 mg/m2, cisplatin 70 mg/m2 i.v. on day 1, fluorouracil 700 mg/m2 continuous infusion for 7 days) every 4 weeks
Study: 27687307
Drug: DCF (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCF (docetaxel 70 mg/m2, cisplatin 70 mg/m2 i.v. on day 1, fluorouracil 700 mg/m2 continuous infusion for 5 days) every 3 weeks
Study: 21549403
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (physiotherapy, corticosteroid injections, oral anti-inflammatory analgesics)
Study: 19140899
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin injection therapy (IIT)
Study: 2648867
Drug: Desipramine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine 200 mg/day
Study: 30872263
Drug: Enzalutamide with
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide with androgen-deprivation therapy
Study: 30872263
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with androgen-deprivation therapy
Study: 23239133
Drug: Reboxetine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (4 mg/day) + Betahistine (48 mg/day)
Study: 17704973
Drug: Synthetic antidepressive
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic antidepressive drugs
Study: 11080605
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy with nutritional approach